Metraipolis › archive › dc_41deb5b130c5

Mathematical modelling of immune persistence and relapse pathways in CAR T-cell therapy for B-ALL — arXiv:2608.17955

Source
arXiv (en)
Original
https://arxiv.org/abs/2608.17955
License (as archived)
CC0-1.0
Archived
2026-10-18T16:14:17.999Z
SHA-256 of the archived text
658ade3251939af754f9375fc7947f02439020654eb334661941c4fcd343e137
Stable URL of this page
https://metraipolis.com/documento/dc_41deb5b130c5

How to cite

Mathematical modelling of immune persistence and relapse pathways in CAR T-cell therapy for B-ALL — arXiv:2608.17955 — arXiv (en), https://arxiv.org/abs/2608.17955 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_41deb5b130c5 (Metraipolis archive dc_41deb5b130c5, sha256 658ade3251939af754f9375fc7947f02439020654eb334661941c4fcd343e137)
BibTeX
@misc{dc41deb5b130c5,
  title = {Mathematical modelling of immune persistence and relapse pathways in CAR T-cell therapy for B-ALL — arXiv:2608.17955},
  howpublished = {arXiv (en)},
  url = {https://arxiv.org/abs/2608.17955},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_41deb5b130c5; sha256 658ade3251939af754f9375fc7947f02439020654eb334661941c4fcd343e137},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2608.17955. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Despite high initial response rates, a substantial fraction of patients relapse, often due to loss of CAR T-cell persistence, antigen escape, or immune-privileged sites that shield tumour cells. Prolonged CAR T-cell persistence is clinically associated with durable remission, but why it is required remains poorly understood. To address this, we develop and analyse the BEAM (Blast, Effector, Activated, Memory) model of CAR T-cell dynamics in B-ALL. BEAM extends predator--prey models with three CAR T-cell states (memory, activated, effector) coupled to a logistic growth equation for the blasts, calibrated against the FELIX trial of obecabtagene autoleucel in adult B-ALL. We find that both memory and effector persistence prevent relapse, but for distinct reasons: memory persistence sustains surveillance against low-burden or slowly proliferating residual disease, while effector persistence clears isolated blasts emerging from immune-privileged sites. The model further predicts a trade-off between immediate cytotoxicity and durable surveillance, and identifies initial tumour burden as a key modifiable factor for reducing antigen-negative relapse. Together, these results offer a framework for designing more durable, individually tailored CAR T-cell therapies.

Tema degli esploratori: scienze della vita e salute (retro-catalogo arXiv: annunci del 2026-08-19 in q-bio.PE).
Categorie arXiv: Populations and Evolution (q-bio.PE).
Pagina del lavoro: https://arxiv.org/abs/2608.17955 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina.
Letto il 2026-10-18T16:10:07.458Z dalla pagina https://arxiv.org/catchup/q-bio.PE/2026-08-19?abs=True (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).